⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20018526 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL28412850 | 0.97 | — | — | |
| Methane SCHEMBL10699216 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL16570059 | 0.97 | — | — | |
| SCHEMBL9542986 | 0.91 | — | — | |
| SCHEMBL22590342 | 0.84 | — | — | |
| SCHEMBL4376350 | 0.84 | — | — | |
| SCHEMBL623203 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL3633714 | 0.82 | THRB (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL31037761 | 0.80 | DPP4 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752150-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB Biopharma SRL (BE) | 2020-12-23 | — | — | EP | claimed |
| WO-2019158731-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-08-22 | — | — | WO | claimed |
| CN-109310668-A | Positive allosteric modulators of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2019-02-05 | — | — | CN | claimed |
| EP-2909212-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | Takeda Pharmaceutical Company Limited (JP) | 2015-08-26 | — | — | EP | claimed |
| WO-2014039831-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-13 | — | — | WO | claimed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | claimed |
| CN-102056927-A | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC | 2011-05-11 | — | — | CN | claimed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | claimed |
| CN-101600706-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2009-12-09 | — | — | CN | claimed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| US-7582123-B2 | Coloring composition comprising at least one azomethine compound with a pyrazolinone unit | L'OREAL S.A. (FR) | 2009-09-01 | — | — | US | claimed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090044348-A1 | Coloring composition comprising at least one azomethine compound with a pyrazolinone unit | L'OREAL S.A. (FR) | 2009-02-19 | — | — | US | claimed |
| CN-1760192-A | Cationic diazo compounds, compositions comprising them, methods for dyeing and kit | OREAL (FR) | 2006-04-19 | — | — | CN | claimed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| WO-1999065909-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0517225-A1 | Aminopyrrolidine platinum compounds, a process for preparing them and pharmaceutical compositions containing them | FERRER INTERNACIONAL, S.A. (ES) | 1992-12-09 | — | — | EP | disclosed |